Autoimmune hepatitis induced by bosentan in a patient with pulmonary arterial hypertension (RCD code: II‐1A.1; VIII)

Oksana Sergeevna Kalashnykova, Larisa Ivanovna Vasilyeva, Alina Vasilevna Khomich

Full Text:

PDF

Abstract


Endothelin receptor antagonist (ERA) therapy‐induced increase in liver transaminases in patients with pulmonary arterial hypertension (PAH) is an adverse effect of bosentan which is not fully understood. A 62‐year‐old female with a 1.5‐year history of progressively worsening dyspnoea was diagnosed with idiopathic PAH (IPAH). After 2 months of PAH treatment with bosentan, levels of liver transaminases were elevated and autoimmune hepatitis was diagnosed. This clinical case demonstrates the challenge of diagnosing autoimmune hepatitis induced by ERA therapy in clinical practice. A thorough understanding of the pathogenesis and clinical presentation of autoimmune hepatitis, as well as the possibility to perform specific investigations with multiple serological markers are crucial for establishing the correct diagnosis. JRCD 2019; 4 (4): xx–xx


Keywords


rare disease; endothelin receptor antagonist; echocardiography; computed tomography; transaminase

References


McGoon MD, Benza RL, Escribano‐Subias P, et al. Pulmonary arterial hypertension: epidemiology and registries. J Am Coll Cardiol 2013; 62 (25 Suppl): 51–59.

Galie N, Humbert M, Vachiery JL, et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Respir J 2015; 46 (4): 903–975.

Galie N, Corris PA, Frost A, et al. Updated treatment algorithm of pulmonary arterial hypertension. J Am Coll Cardiol 2013; 62 (25 Suppl): 60–72.

Galie N, Manes A, Branzi A. The endothelin system in pulmonary arterial hypertension. Cardiovasc Res 2004; 61 (2): 227–237.

Kim NHS, Rubin LJ. Endothelin in health and disease: endothelin receptor antagonists in the management of pulmonary artery hypertension. J Cardiovasc Pharmacol Ther 2002;7 (1): 9–19

Pulido T, Adzerikho I, Channick RN, et al. Macitentan and morbidity and mortality in pulmonary arterial hypertension. N Engl J Med 2013; 369 (9): 809–818.

Galie N, Badesch D, Oudiz R, et al. Ambrisentan therapy for pulmonary arterial hypertension. J Am Coll Cardiol 2005; 46 (3): 529–535.

Wilkins M, Paul G, Strange J, et al. Sildenafil versus endothelin receptor antagonist for pulmonary hypertension (SERAPH) study. Am J Respir Crit Care Med 2005;171:1292–1297.

Barst RJ, Mubarak KK, Machado RF, et al. Exercise capacity and hemodynamics in patients with sickle cell disease and pulmonary hypertension treated with bosentan: results of the ASSET studies. Br J Haematol 2010; 149: 426–435.

Galie N, Beghetti M, Gatzoulis M, et al. Bosentan therapy in patients with Eisenmenger syndrome: a multicenter, double‐blind, randomized, placebo‐controlled study. Circulation 2006; 114 (1): 48–54.

Galie N, Rubin LJ, Hoeper MM, et al. Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double‐blind, randomized controlled trial. Lancet 2008; 371: 2093–2100.

Humbert M, Segal ES, Kiely DG, et al. Results of European post‐marketing surveillance of bosentan in pulmonary hypertension. Eur Respir J 2007;30 (2): 338–344.

Dingemanse J, van Giersbergen P. Clinical pharmacology of bosentan, a dual endothelin receptor antagonist. Clin Pharmacokinet 2004; 43 (15):1089–1115.

Lepist E, Gillies H, Smith W, et al. Evaluation of the endothelin receptor antagonists ambrisentan, bosentan, macitentan, and itaxsentan as hepatobiliary transporter inhibitors and substrates in sandwich‐cultured human hepatocytes. PloS One 2014; 9 (1): e87 548.

Ling L, Kuc RE, Maguire JJ, et al. Comparison of endothelin receptors in normal versus cirrhotic human liver and in the liver from endothelial cell‐specific ETB knockout mice. Life Sci 2012; 91(13–14): 716–722.

Roustit M, Fonrose X, Montani D, et al. CYP2C9, SLCO1B1, SLCO1B3, and

ABCB11 polymorphisms in patients with bosentan‐induced liver toxicity.

Clin Pharmacol Ther 2014; 95 (6): 583–585.

Kwo PY, Cohen SM, Lim JK. ACG Clinical Guideline: Evaluation of Abnormal Liver Chemistries. Am J Gastroenterol 2017;112:18–35. doi:10.1038/ajg.2016.517.

European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Autoimmune hepatitis. J Hepatol 2015; 63: 971–1004

Berger RM, Haworth SG, Bonnet D, et al. FUTURE‐2: Results from an open‐label, long‐term safety and tolerability extension study using the pediatric Formulation of bosentan in pulmonary arterial hypertension. Int J Cardiol 2016; 202: 52–58. doi:10.1016/j. ijcard.2015.08.080

Naito A, Terada J, Tanabe N, et al. Autoimmune Hepatitis in a Patient

with Pulmonary Arterial Hypertension Treated with Endothelin Receptor

Antagonists. Intern Med 2014; 53: 771–775. doi:10.2169/ internalmedi‐

cine.53.1362

Klein R, Hintz E, Staehler G. Exacerbation of AIH in a patient with an AIH/systemic sclerosis overlap syndrome and pulmonary arterial hypertension treated with the endothelin‐1 receptor antagonist sitaxentan. BMJ Case Re 2012. doi:10.1136/bcr- 01‐2012‐5494




DOI: http://dx.doi.org/10.20418%2Fjrcd.vol4no3.396

Refbacks

  • There are currently no refbacks.
Journal of Rare Cardiovascular Diseases (JRCD)
John Paul II Hospital in Kraków, 80 Prądnicka Str., 31-202 Kraków, Poland
Phone: +48 (12) 614 33 99, +48 (12) 614 34 88 Fax: +48 (12) 614 34 88
e-mail: rarediseases@szpitaljp2.krakow.pl
Published by SoftQ sp. z o.o.
ul. Oleandry 2, 30-063 Kraków, Poland
Phone: +48 (12) 444 1650 Fax: +48 (12) 444 1659
e-mail: softq@softq.pl